SCHEDULE: PAVmed Inc. Ownership Update

Tasso Partners, LLC and Dana Carrera report combined beneficial ownership of 15.3% of PAVmed Inc. common stock as of March 27, 2026.

Summary

• Tasso Partners, LLC and Dana Carrera have filed an amendment to their Schedule 13G, reporting their beneficial ownership of PAVmed Inc. common stock.
• As of March 27, 2026, Tasso Partners, LLC holds 912,996 shares, representing 14.3% of the outstanding common stock.
• Dana Carrera beneficially owns an aggregate of 974,246 shares, representing 15.3% of the outstanding common stock.
• This aggregate includes 912,996 shares held by Tasso Partners, LLC, and 61,250 shares owned directly by the GCL Family Trust, of which Dana Carrera is the trustee.
• The filing also notes 5,365 warrants held by Tasso Partners, LLC, exercisable for up to 825,385 shares of common stock, subject to a 9.99% ownership restriction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on ownership stakes and not indicative of immediate company performance or strategic shifts.

Positives

• Significant beneficial ownership reported by Tasso Partners, LLC and Dana Carrera, indicating substantial investor interest.
• The ownership percentage is based on a clear denominator of 6,383,089 shares of common stock outstanding as of March 27, 2026.

Risks

• The warrants held by Tasso Partners, LLC are convertible into a substantial number of shares, which could lead to dilution if exercised.
• A contractual 9.99% ownership restriction applies to the shares issuable upon exercise of the warrants, potentially limiting future ownership increases without further action.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. The future outlook is primarily related to the potential conversion of warrants and associated ownership restrictions.

Management Comments

• Tasso Partners, LLC and Dana Carrera have entered into a Joint Filing Agreement to jointly file the Schedule 13G and its amendments.
• The filing states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to report their stakes in publicly traded companies. This filing indicates a substantial, but not controlling, ownership position in PAVmed Inc. by Tasso Partners, LLC and Dana Carrera.

Stakeholder Impact

• Shareholders: The filing provides transparency on significant ownership stakes, which can influence market perception. Potential dilution from warrant exercise is a consideration.
• Management: The reporting persons' significant stake may influence discussions regarding corporate strategy and governance.
• Creditors: No direct impact mentioned, but significant ownership changes can sometimes signal shifts in company stability.

Next Steps

• Monitoring of Tasso Partners, LLC and Dana Carrera's beneficial ownership in PAVmed Inc. will continue.
• Potential exercise of warrants by Tasso Partners, LLC could lead to changes in the number of outstanding shares and ownership percentages.

Key Dates

Keywords

PAVmed Inc., Schedule 13G, Tasso Partners, LLC, Dana Carrera, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Ownership Threshold